Skip to main content

Site navigation

  • University of Technology Sydney home
  • Home

    Home
  • For students

  • For industry

  • Research

Explore

  • Courses
  • Events
  • News
  • Stories
  • People

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt
  • Study at UTS

    • arrow_right_alt Find a course
    • arrow_right_alt Course areas
    • arrow_right_alt Undergraduate students
    • arrow_right_alt Postgraduate students
    • arrow_right_alt Research Masters and PhD
    • arrow_right_alt Online study and short courses
  • Student information

    • arrow_right_alt Current students
    • arrow_right_alt New UTS students
    • arrow_right_alt Graduates (Alumni)
    • arrow_right_alt High school students
    • arrow_right_alt Indigenous students
    • arrow_right_alt International students
  • Admissions

    • arrow_right_alt How to apply
    • arrow_right_alt Entry pathways
    • arrow_right_alt Eligibility
arrow_right_altVisit our hub for students

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt

POPULAR LINKS

  • Apply for a coursearrow_right_alt
  • Current studentsarrow_right_alt
  • Scholarshipsarrow_right_alt
  • Featured industries

    • arrow_right_alt Agriculture and food
    • arrow_right_alt Defence and space
    • arrow_right_alt Energy and transport
    • arrow_right_alt Government and policy
    • arrow_right_alt Health and medical
    • arrow_right_alt Corporate training
  • Explore

    • arrow_right_alt Tech Central
    • arrow_right_alt Case studies
    • arrow_right_alt Research
arrow_right_altVisit our hub for industry

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt

POPULAR LINKS

  • Find a UTS expertarrow_right_alt
  • Partner with usarrow_right_alt
  • Explore

    • arrow_right_alt Explore our research
    • arrow_right_alt Research centres and institutes
    • arrow_right_alt Graduate research
    • arrow_right_alt Research partnerships
arrow_right_altVisit our hub for research

For you

  • Libraryarrow_right_alt
  • Staffarrow_right_alt
  • Alumniarrow_right_alt
  • Current studentsarrow_right_alt

POPULAR LINKS

  • Find a UTS expertarrow_right_alt
  • Research centres and institutesarrow_right_alt
  • University of Technology Sydney home
University of Technology Sydney home University of Technology Sydney home
  1. home
  2. arrow_forward_ios ... Newsroom
  3. arrow_forward_ios ... 2023
  4. arrow_forward_ios 03
  5. arrow_forward_ios NSAIDs for pain: are we underutilising a good analgesic? | IMPACCT news

NSAIDs for pain: are we underutilising a good analgesic? | IMPACCT news

14 March 2023

Pain in palliative care remains a challenging symptom to treat. Non-steroidal anti-inflammatory drugs (NSAIDs) have been around for decades, but used less and less over concerns about safety. Are these fears justified for an effective drug?

Clinician examining patient for back pain

Key points

  • NSAIDs are non-sedating, non-addictive and effective, but use has been declining over concerns about acute kidney injury and bleeding.
  • This is the first study to rigorously assess those risks in a real-world palliative population.
  • Serious harm was seen in only 2% of patients prescribed NSAIDs and none stopped the NSAID due to harm.
  • NSAIDs may be safer than previously thought and may be an important and underutilised class of analgesic. 

NSAIDs and current practice

There has been little doubt about the effectiveness of NSAIDs for a variety of types of pain and clinical settings for many decades.

NSAIDs are recommended for post-operative pain, musculoskeletal pain, and the first step of the WHO analgesia ladder for cancer-related pain. They are available over the counter in Australasia for patient self-administration for minor ailments.

In palliative care, they are particularly effective for cancer-related bone pain, non-malignant musculoskeletal pain, soft tissue invasion (particularly pleura) by tumours, and a variety of other pains.

However, use of NSAIDs has been falling since the 2000s due to concerns about safety. NSAIDs are associated with some serious harms including acute kidney injury and bleeding, Studies show it is concern over these serious drug reactions that cause clinicians not to prescribe NSAIDs.

Old drugs, new opportunities

More recently, a new generation of NSAIDs has emerged - the COX-2 selective ‘coxibs’. These are associated with less bleeding than traditional NSAIDs, but at the cost of increased risk of cardiovascular disease. 

The increased cardiovascular risk is very small and takes some time to develop, whereas the reduction in bleeding is larger and  the bleeding risk is increased from the first dose. As such, we argue in a recent study that coxibs are a more rationale choice in palliative care and provide a potentially safe new option.

Evaluating the risks of NSAIDs for patients receiving palliative care

Although adverse reactions are the main barrier to prescribing NSAIDs in palliative care, no studies until now have rigorously evaluated the risk of NSAIDs in palliative patients.

The IMPACCT Rapid Program investigates the real-world harms and benefits of a variety of palliative interventions. We conducted a Rapid series to assess the harms of NSAIDs prospectively, systematically, and rigorously in 92 real-world patients from 14 sites across Australia, Aotearoa New Zealand and the UK.

We found that in spite of clinician concerns, only 3% of patients had episodes of bleeding or acute kidney injury in the month after starting NSAIDs. Only 2% of patients suffered serious harm and none stopped their NSAID due to harm. In contrast, almost 90% of patients had benefit and 65% had benefit without any harm. Half of the patients received the newer COX-2 selective NSAIDs.

Importantly, this study  included many patients with significant risk factors for acute kidney injury and bleeding. These patients would never have been included in a randomised trial, and the study results show that NSAIDs can be safe and effective even outside of the ‘perfectly selected’ patient populations.

Implications for practice

The study suggests that NSAIDs are safer in a real-world palliative care setting than previously thought. NSAIDs are cheap, non-addictive, non-sedating, and effective analgesics. They may be an underutilised tool in the analgesic arsenal. Safety data from this study may be exactly what is needed to allow clinicians in palliative care to fully utilise these important drugs.

Reference

McNeill R, Boland JW, Wilcock A, et al. Non-steroidal anti-inflammatory drugs for pain in hospice/palliative care: an international pharmacovigilance study. BMJ Support Palliat Care 2023; spcare-2022-004154.

 

Dr Richard McNeill has short hair and a beard and wearing a checked shirt. He is smiling at the camera.

Dr Richard McNeill is a palliative care physician and clinical pharmacologist in New Zealand. He is currently employed at Nurse Maude Hospice in Christchurch, and he is also a research fellow at the University of Otago. He is undertaking a masters in clinical informatics. Richard has an interest in research involving all aspects of pharmacotherapy in palliative care.

 

Byline

Dr Richard McNeill
Share
Share this on Facebook Share this on Twitter Share this on LinkedIn
Back to IMPACCT news

Related News

  • Male patient sits in a chair with his hand held to his head. He has a beard and short hair. He is wearing a white tee shirt with a dark coloured jacket.
    Cyclizine for nausea
  • Young businessman in office wearing a play blue jumper over a white shirt. He has glasses on and he is smiling at the camera.
    IMPACCT Rapid Program - new user guides for simpler clinician participation

Acknowledgement of Country

UTS acknowledges the Gadigal People of the Eora Nation and the Boorooberongal People of the Dharug Nation upon whose ancestral lands our campuses now stand. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands. 

University of Technology Sydney

City Campus

15 Broadway, Ultimo, NSW 2007

Get in touch with UTS

Follow us

  • Instagram
  • LinkedIn
  • YouTube
  • Facebook

A member of

  • Australian Technology Network
Use arrow keys to navigate within each column of links. Press Tab to move between columns.

Study

  • Find a course
  • Undergraduate
  • Postgraduate
  • How to apply
  • Scholarships and prizes
  • International students
  • Campus maps
  • Accommodation

Engage

  • Find an expert
  • Industry
  • News
  • Events
  • Experience UTS
  • Research
  • Stories
  • Alumni

About

  • Who we are
  • Faculties
  • Learning and teaching
  • Sustainability
  • Initiatives
  • Equity, diversity and inclusion
  • Campus and locations
  • Awards and rankings
  • UTS governance

Staff and students

  • Current students
  • Help and support
  • Library
  • Policies
  • StaffConnect
  • Working at UTS
  • UTS Handbook
  • Contact us
  • Copyright © 2025
  • ABN: 77 257 686 961
  • CRICOS provider number: 00099F
  • TEQSA provider number: PRV12060
  • TEQSA category: Australian University
  • Privacy
  • Copyright
  • Disclaimer
  • Accessibility